RHYTHM PHARMACEUTICALS, INC. Interest Expense
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Interest Expense of $4.75 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-07
- RHYTHM PHARMACEUTICALS, INC. interest expense for the quarter ending 2024-03-31 was $4.75M, a 55.34% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-12-31 was $4.55M, a 51.11% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-09-30 was $3.15M, a 46.88% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-06-30 was $3.30M, a 7080.43% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. interest expense for fiscal 2023 was $13.89M, a 167.10% increase from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. interest expense for fiscal 2022 was $5.20M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $4.75M 10-Q · filed 2024-05-07 | $9.30M derived: sum of 2 quarters · filed 2024-05-07 | $12.45M derived: sum of 3 quarters · filed 2024-05-07 | $15.76M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | $4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $7.70M derived: sum of 2 quarters · filed 2024-02-29 | $11.00M derived: sum of 3 quarters · filed 2024-02-29 | $13.89M 10-K · filed 2024-02-29 |
| 2023-09-30 | $3.15M 10-Q · filed 2023-11-08 | $6.45M derived: sum of 2 quarters · filed 2023-11-08 | $9.34M 10-Q · filed 2023-11-08 | $12.52M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-06-30 | $3.30M 10-Q · filed 2023-08-01 | $6.45M 10-Q · filed 2023-08-01 | $9.38M derived: sum of 3 quarters · filed 2024-05-07 | $11.52M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-03-31 | $3.06M 10-Q · filed 2024-05-07 | $6.07M derived: sum of 2 quarters · filed 2024-05-07 | $8.22M derived: sum of 3 quarters · filed 2024-05-07 | $8.26M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $3.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $5.16M derived: sum of 2 quarters · filed 2024-02-29 | $5.20M derived: sum of 3 quarters · filed 2024-02-29 | $5.20M 10-K · filed 2024-02-29 |
| 2022-09-30 | $2.14M 10-Q · filed 2023-11-08 | $2.19M derived: sum of 2 quarters · filed 2023-11-08 | $2.19M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $46.00K 10-Q · filed 2023-08-01 | $46.00K 10-Q · filed 2023-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |